Videos

A key opinion leader explains whether doublet regimens still have a place in transplant-ineligible multiple myeloma treatment.

Panelists provide comprehensive insight on treatment strategies specific to the setting of low-volume metastatic prostate cancer.

Expert oncologists review the selection of apalutamide + androgen deprivation therapy in this patient scenario of metastatic castration-sensitive prostate cancer.

Expert oncologists look toward future utilization of circulating tumor DNA testing and consider how the field of oncology may evolve.

Shared insight on how circulating tumor DNA may be used in real-world clinical practice to improve the value of cancer care.

Centering discussion on a scenario of acute graft vs host disease, expert panelists consider optimal workup of a patient showing signs of GVHD.

Shared insight on the pathophysiology of graft vs host disease, with specific regard for differences between acute GVHD vs chronic GVHD.

Trevor M. Feinstein, MD, spoke about how quality of life was improved for patients with EGFR wild-type stage IIIB/IV non–small cell lung cancer receiving plinabulin in addition to docetaxel the phase 3 DUBLIN-3 trial.

Angela DeMichele, MD, MSCE, spoke about the I-SPY2 trial, which evaluates patients with early breast cancer who are treated with experimental neoadjuvant systemic therapy regimens.

Alexis A. Thompson, MD, MPH, reviewed unmet needs for patients with β-thalassemia who may now receive betibeglogene autotemcel.

Data from the phase 2 DYNAMIC trial show that a circulating tumor DNA–guided approach to adjuvant therapy selection may be feasible for patients with stage II colorectal cancer, but Tanios S. Bekaii-Saab, MD, is skeptical about its readiness for prime time.

Paul G. Richardson, MD, presented data from the phase 3 DETERMINATION study at 2022 ASCO and theorized how these findings could extend to similar regimens in newly diagnosed multiple myeloma.

Focusing broadly on breast cancer, expert oncologists detail how ctDNA may impact patient monitoring and treatment decisions moving forward.

Moving on to the second patient scenario, panelists elucidate the value of ctDNA in patients with triple-negative breast cancer.

A brief discussion on the toxicities and drug-drug interactions associated with frontline therapies in metastatic CSPC and when it would be appropriate to alter treatment to mitigate toxicity.

Focused discussion on drug and patient factors that aid in the selection of frontline therapy for metastatic castration-sensitive prostate cancer.

Alexis A. Thompson, MD, MPH, spoke about the use of betibeglogene autotemcel for patients with β-thalassemia.

Rafael Fonseca, MD, describes key data from the MAIA and SWOG 0777 studies investigating triplet regimens in multiple myeloma treatment, and how the results compare.

Dr Luciano Costa provides an overview of the currently available treatment options for patients with transplant-ineligible, newly diagnosed multiple myeloma.

Hematologist/oncologists provide a broad overview of the pharmacologic agents used to prevent graft vs host disease at their institutions.

Expert panelists elucidate the occurrence of graft vs host disease in patients receiving either stem cell or allogeneic transplantation.

Data from the PARADIGM trial that were presented at 2022 ASCO demonstrated that panitumumab plus FOLFOX should be standard of care for patients with left-sided, RAS wild-type colorectal cancer, according to Tanios S. Bekaii-Saab, MD.

Valentina Boni, MD, PhD, spoke about numerous trials in the breast cancer space presented at 2022 ASCO.

Tanios S. Bekaii-Saab, MD, discussed how data from clinical trials examining different targeted strategies in colorectal cancer will transform the way in which patients with this malignancy are seen and treated.

Ian D. Davis, MBBS, PhD, spoke about the subgroup analysis of the ENZAMET trial which analyzed enzalutamide in metastatic hormone-sensitive prostate cancer.

The panel closes their discussion on myelofibrosis treatment updates by sharing clinical pearls for community oncologists.

Experts delve into the unmet needs in the myelofibrosis treatment landscape and highlight promising ongoing clinical trials.

At 2022 ASCO, Tanios S. Bekaii-Saab, MD, talks about how data from the ongoing MOUNTAINEER trial investigating trastuzumab plus tucatinib in HER2-positive metastatic colorectal cancer and other similar trials may impact the standard of care going forward.

Shared insight on the frontline use of chemotherapy options for patients with metastatic CSPC in the context of AR-targeted therapies.

After reviewing a patient scenario of metastatic castration-sensitive prostate cancer, expert panelists break down frontline treatment options in this setting.